HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
PxQ9ksDuHQnkMf2d